Holen Sie sich die Stockscreener-App
26.10
13.12%
-3.94
Handel nachbörslich:
25.48
-0.62
-2.38%
Schlusskurs vom Vortag:
$30.04
Offen:
$29.3
24-Stunden-Volumen:
2.25M
Relative Volume:
2.01
Marktkapitalisierung:
$1.43B
Einnahmen:
$199.89M
Nettoeinkommen (Verlust:
$52.48M
KGV:
30.71
EPS:
0.85
Netto-Cashflow:
$61.15M
1W Leistung:
-20.91%
1M Leistung:
+2.11%
6M Leistung:
+171.03%
1J Leistung:
+102.95%
1-Tages-Spanne:
$24.50
$29.44
1-Wochen-Bereich:
$24.50
$33.13
52-Wochen-Spanne:
$5.35
$38.69
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Vergleichen Sie STOK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
26.10 | 1.65B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-18 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics (STOK): JP Morgan Raises Price Target, Mainta - GuruFocus
Live market analysis of Stoke Therapeutics Inc.Weekly Profit Report & Daily Volume Surge Trade Alerts - newser.com
Why Stoke Therapeutics Inc. stock attracts high net worth investorsQuarterly Growth Report & Free Expert Verified Stock Movement Alerts - newser.com
Can Stoke Therapeutics Inc. stock sustain institutional interestMarket Activity Summary & Daily Momentum Trading Reports - newser.com
What insider trading reveals about Stoke Therapeutics Inc. stockGold Moves & High Accuracy Trade Alerts - newser.com
Using portfolio simulators with Stoke Therapeutics Inc. includedJuly 2025 Institutional & Safe Capital Investment Plans - newser.com
What technical models suggest about Stoke Therapeutics Inc.’s comebackJuly 2025 Highlights & Risk Managed Investment Strategies - newser.com
Is Stoke Therapeutics Inc. stock a good choice for value investorsQuarterly Portfolio Review & Reliable Volume Spike Trade Alerts - newser.com
Does Stoke Therapeutics Inc. show high probability of reboundWeekly Stock Summary & AI Powered Market Entry Ideas - newser.com
Will Stoke Therapeutics Inc. stock maintain momentum in 2025Market Sentiment Summary & Fast Exit/Entry Strategy Plans - newser.com
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Stoke Therapeutics Shares Plunge Following Clinical Trial Data Release - AD HOC NEWS
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 6.3%Should You Sell? - MarketBeat
Stoke Therapeutics Inc expected to post a loss of 57 cents a shareEarnings Preview - TradingView
Exit strategy if you’re trapped in Stoke Therapeutics Inc.July 2025 Macro Moves & Weekly High Return Opportunities - newser.com
Stoke Therapeutics, Inc. (STOK) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Total debt per share of Stoke Therapeutics, Inc. – BER:0GT - TradingView
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates - Yahoo Finance
Stoke Therapeutics (STOK) Price Target Increased by 16.51% to 28.79 - Nasdaq
Stoke Therapeutics (STOK) Projected to Post Earnings on Tuesday - MarketBeat
Will Stoke Therapeutics Inc. stock maintain dividend yieldExit Point & AI Forecast for Swing Trade Picks - Fundação Cultural do Pará
Why Stoke Therapeutics Inc. stock is popular among millennialsTrade Performance Summary & Stock Market Timing Techniques - fcp.pa.gov.br
Take Profit: Is Stoke Therapeutics Inc. stock a good choice for value investorsTrade Risk Summary & Target Return Focused Stock Picks - fcp.pa.gov.br
Dravet Syndrome Pipeline 2025: Key Developments, Emerging - openPR.com
How Stoke Therapeutics Inc. stock trades before earningsDividend Hike & Step-by-Step Swing Trade Plans - Fundação Cultural do Pará
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):